• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rapid Start
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)

      Discover Clario's AI solutions, where innovation meets expertise. Since 2018, we have revolutionized clinical trial endpoint analyses with more than 30 AI-enabled solutions across 600+ active trials, enhancing data quality and patient privacy while expediting data collection processes.

      Go to page
    • Cardiac Solutions
      • Cardiac Solutions
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Imaging Platform
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion for Clinical Trials
      • Precision Motion for Research
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, and more.)
      • Virtual Home Spirometry
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials

      All the precision endpoint technology and services your virtual or hybrid trial needs to deliver more certain outcomes.

      Go to page
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Neuroscience
    • Dermatology
    • Oncology
    • Gastroenterology
    • Ophthalmology
    • Hepatology
    • Respiratory Solutions
    • Infectious Diseases
    • Type 2 Diabetes and Obesity
    • Musculoskeletal
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rapid Start
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)
    • Cardiac Solutions
      • Cardiac Solutions
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Imaging Platform
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion for Clinical Trials
      • Precision Motion for Research
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, and more.)
      • Virtual Home Spirometry
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials
      • Decentralized Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology
    • Ophthalmology
    • Type 2 Diabetes and Obesity
    • Respiratory Solutions
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home About Newsroom Transforming clinical trial endpoint analysis: Clario implements over 30 AI solutions to deliver faster and accurate results 

Transforming clinical trial endpoint analysis: Clario implements over 30 AI solutions to deliver faster and accurate results 

AI and ML solutions are enhancing Clario’s scientists’ abilities to deliver a more efficient, accurate and faster analysis of trial participant data collection. These novel tools optimize operations, integrate platforms, strengthen patient privacy and increase data quality while reducing errors. 

  • Clario has implemented over 30 AI solutions with more than half integrated directly into Clario platforms since 2018 through in-house development and AI-driven strategic partnerships. 
  • With the support of AI and ML, Clario scientists are augmenting their abilities to deliver enhanced quality in data collection, reduce the potential for errors and provide faster data analysis without compromising accuracy. 
  • 70+ clinical trials are enrolled in various Clario AI models across our platforms. 

PHILADELPHIA, PA – May 23, 2023 – Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today revealed the significant progress it has made in the integration of Artificial Intelligence (AI) and Machine Learning (ML) into clinical trial data collection through their own development and strategic partnerships. Over 30 solutions have been applied, with more than half of them already active on various Clario platforms. These integrations have led to a remarkable evolution in the way clinical trial endpoint analyses are conducted at the company. By combining AI tools with deep scientific expertise, Clario is achieving faster and more accurate results than ever before. Furthermore, this integration has enhanced operational efficiencies and patient privacy protection. 

“When it comes to AI technology and clinical trials, it’s not about one single solution,” said Todd Rudo, Chief Medical Officer, Clario. “Clinical trials are complicated and unique to the medicine they are researching, so they require bespoke solutions. This is why Clario is developing AI solutions that tackle specific challenges across Cardiac Safety, eCOA, Imaging, Precision Motion and Respiratory for trial endpoint analysis. We currently have over 70 clinical trials enrolled in our various AI models, and our clients and their patients are already realizing the benefits: enhancements in our ability to collect a wide range of digital data types and subsequently analyze them faster and more accurately.” 

“AI is transforming clinical trials, but we have to be thoughtful in how we develop it for such a complex area. Clario’s innovative approach is to work with our scientific experts to identify meaningful applications of artificial intelligence to improve our performance in data collection and analysis without compromising safety or quality assessments. AI is not a replacement for our scientists but an effective tool to assist them in their routine work. AI in clinical trials is clearly moving out of its infancy, and we are excited to be at the forefront of progress in this ever-evolving landscape,” said Achim Schülke, EVP Chief Innovation Officer, Clario. 

Since 2018, Clario has applied over 30 AI solutions that enhance scientists’ data endpoint analyses by optimizing operations, integrating platforms, strengthening patient privacy and increasing quality and precision while reducing errors. The AI solutions across Clario’s technology platform include: 

  • Cardiac Safety: To increase data quality and reduce the risk of missing data, AI-supported quality assessments for continuous 12-lead ECG recordings are under development which permit the rapid identification of poor-quality recordings, enabling the opportunity to rapidly address any issues directly at the site level. 
  • eCOA: To improve patient safety and data quality, the eCOA Science risk monitoring analytics solution identifies potential issues early throughout clinical trials to enable corrective action. In addition, consistency checks across multiple eCOA instruments are in place to ensure more robust scientific data and improved investigator oversight and experience. 
  • Imaging: Receipt, processing, quality control and analysis are faster than ever with the help of AI tools such as auto-labelling that automatically identifies up to 10,000 images (e.g., MRI, X-ray) a week, facial masking to enhance patient privacy and reduce manual quality control time per video from one hour to one minute, and automated motion detection for image quality metrics. Clario also uses powerful AI frameworks for image classifications, segmentations, landmark detections, and regions of interest. 
  • Respiratory: AI algorithms can now automatically analyze spirometry loops to support immediate quality control by detecting technical errors, ensuring consistent and objective data collection across clinical sites and trial environments. Potentially problematic loops can be flagged for further review by a trained specialist and can be used to help further enhance algorithms to support future studies. 

Clario’s innovation, development and implementation of multiple AI solutions for data endpoint analysis is transforming efficiency, accuracy and speed in clinical trials.


About Clario

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints. 

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 26,000 clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012. 

For more information, go to Clario.com or follow us on LinkedIn. 

Media Contact:
David Malley
Director of Brand, Content Strategy, and Communications
[email protected]

Back to newsroom
Share
Twitter Facebook LinkedIn

Related News

See all news

Clario Announces Completion of Acquisition of WCG’s eCOA Business

May 6, 2025 Read more

Clario collaborates with AWS to push new boundaries in clinical data analysis with generative AI 

April 16, 2025 Read more

Clario announces acquisition of imaging provider NeuroRx

March 17, 2025 Read more
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum